Role of Immune Checkpoint Inhibitors in the Management of Metastatic NSCLC without Actionable Mutations with Dr Corey Langer
Dr Corey Langer from the Abramson Cancer Center at the University of Pennsylvania discusses recently published and emerging data on the role of immune checkpoint inhibitors in the treatment of metastatic non-small cell lung cancer without actionable mutations. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayNSCLCWT21)
